Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism MASP2 inhibitors(Mannan-binding lectin serine protease 2 inhibitors), TNFRSF13B inhibitors(Tumor necrosis factor receptor superfamily member 13B inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Diseases | Preclinical | CN | - | |
Systemic Lupus Erythematosus | Preclinical | CN | - |